Summary
Sunshine BioPharma Inc (Sunshine BioPharma), a subsidiary of Advanomics Corp is a pharmaceutical company that provides research, development and commercialization of drugs for treating cancer disease. The company’s drug candidate is Adva-27a, a small molecule against different types of multidrug resistant cancer cell lines. It also provides difluoro-etoposide, which is a multipurpose anti-tumor compound. The company offers products for breast cancer, uterine carcinoma, pancreatic cancer and small-cell lung cancer, kidney cancer, and squamous-cell carcinomas. Sunshine BioPharma is headquartered in Montreal, Quebec, Canada.
Sunshine Biopharma Inc (SBFM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Sunshine Biopharma Acquires Remaining Patent Rights for Adva-27a from Advanomics 12
Sunshine BioPharma Acquires Adva-27a Patents From Institut National des Sciences Appliquees 13
Venture Financing 14
Actinium Pharma Raises US$5 Million In First Closing Of Venture Financing Round 14
Actinium Pharma Secures US$4.1 Million In Initial Closing Of Series E Financing Round 16
Partnerships 17
Actinium Pharma Partners with Vector Oncology 17
Actinium Pharma Enters into Agreement with Medpace 18
Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 19
Sunshine Biopharma Enters Into Co-Development Agreement With Jewish General Hospital 20
Sunshine Biopharma Enters Into Collaboration With The Research Foundation Of The State University of New York 22
Licensing Agreements 23
Sunshine Biopharma Enters into Licensing Agreement 23
Sunshine Biopharma Enters into Licensing Agreement for Anastrozole 24
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 25
Equity Offering 27
Actinium Pharma Raises USD10 Million in Public Offering of Shares 27
Actinium Pharma Raises USD5 Million in Private Placement of Shares 29
Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 31
Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 33
Sunshine Biopharma to Raise up to USD2.5 Million in Private Placement of Shares 35
Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For US$3.3 Million 36
Actinium Pharma Completes Private Placement Of Shares For US$3.5 Million Upon Exercise Of Warrants 37
Actinium Pharma Plans IPO 38
Sunshine Biopharma Completes Private Placement Of Shares For US$0.2 Million 39
Acquisition 40
Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 40
Sunshine Biopharma Inc - Key Competitors 42
Key Employees 43
Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sunshine Biopharma Inc, Deals By Therapy Area, 2010 to YTD 2016 9
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Sunshine Biopharma Acquires Remaining Patent Rights for Adva-27a from Advanomics 12
Sunshine BioPharma Acquires Adva-27a Patents From Institut National des Sciences Appliquees 13
Actinium Pharma Raises US$5 Million In First Closing Of Venture Financing Round 14
Actinium Pharma Secures US$4.1 Million In Initial Closing Of Series E Financing Round 16
Actinium Pharma Partners with Vector Oncology 17
Actinium Pharma Enters into Agreement with Medpace 18
Actinium Pharma Enters into Co-Development Agreement with Albert Einstein College of Medicine 19
Sunshine Biopharma Enters Into Co-Development Agreement With Jewish General Hospital 20
Sunshine Biopharma Enters Into Collaboration With The Research Foundation Of The State University of New York 22
Sunshine Biopharma Enters into Licensing Agreement 23
Sunshine Biopharma Enters into Licensing Agreement for Anastrozole 24
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 25
Actinium Pharma Raises USD10 Million in Public Offering of Shares 27
Actinium Pharma Raises USD5 Million in Private Placement of Shares 29
Actinium Pharma Raises USD20 Million in Public Offering of Shares and warrants 31
Actinium Pharma Raises USD13.7 Million in Public Offering of Shares 33
Sunshine Biopharma to Raise up to USD2.5 Million in Private Placement of Shares 35
Actinium Pharma Completes Second Tranche Of Private Placement Of Securities For US$3.3 Million 36
Actinium Pharma Completes Private Placement Of Shares For US$3.5 Million Upon Exercise Of Warrants 37
Actinium Pharma Plans IPO 38
Sunshine Biopharma Completes Private Placement Of Shares For US$0.2 Million 39
Cactus Ventures Completes Acquisition Of Actinium Pharma In Reverse Takeover Transaction 40
Sunshine Biopharma Inc, Key Competitors 42
Sunshine Biopharma Inc, Key Employees 43
Sunshine Biopharma Inc, Subsidiaries 44
List of Figures
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Sunshine Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
